Rational polypharmacological targeting of FLT3, JAK2, ABL, and ERK1 suppresses the adaptive resistance to FLT3 inhibitors in AML
Sign Up to like & getrecommendations! Published in 2022 at "Blood Advances"
DOI: 10.1182/bloodadvances.2022007486
Abstract: Key Points • JAK2, ABL, and MAPK signaling drive adaptive resistance to FLT3 inhibitors.• Polypharmacological targeting of FLT3, JAK2, ABL, and MAPK signaling provides a durable response in AML. read more here.
Keywords: flt3 inhibitors; adaptive resistance; jak2 abl; targeting flt3 ... See more keywords